Skip navigation
Watchlist Sponsored By :

Current DateTime: 01:27:39 24 Jul 2008
LinksList Documentid: 24355697

Current DateTime: 01:27:39 24 Jul 2008
LinksList Documentid: 24890560
  • Texas is Tops in 2008

      Texas knocked out last year's top state for business, Virginia. How did your state fare in our annual study?

  • Powering the Planet

      Energy has become the most common denominator in the global economy. Ultimately, it may be the great unifier. After all, imagine a world without energy, affordable energy.

  • Apple & The New iPhone

      Second acts should not be taken for granted. Apple and Steve Jobs have yet to make that mistake and they're unlikely to do so with the launch of the new iPhone.

Bloodthinner Plavix Gets Big Boost in New  Study
By Mike Huckman, CNBC Pharmaceuticals Reporter | 05 Feb 2008 | 04:37 PM ET
Font size:

Heart patients with drug-coated stents who stop taking the popular bloodthinner Plavix are quickly put at a higher risk of death, according to a new study published in the "Journal of the American Medical Association."

The finding could boost sales of the blockbuster drug made by Bristol-Myers Squibb [BMY  Loading...      ()   ] and Sanofi-Aventis [SNY  Loading...      ()   ].

Drug-coated stents prop open clogged arteries, but some studies say that months or years later potentially fatal blood clots form.  Patients are put on Plavix to help prevent that.

Researchers who looked at the medical records of more than 3-thousand VA patients say within three months of going off the drug there was a significantly higher or nearly double the risk of death or having a heart attack.

Medical groups including the American Heart Association and the American College of Cardiology recently issued guidelines requiring drug-coated stent patients stay on Plavix for at least a year, maybe longer.

The JAMA study suggests those guidelines be revisited and that patients may need to stay on Plavix indefinitely, similar to people who take an aspirin a day to try to stave off a heart attack.

Plavix is among the top-selling drugs in the world.  One of the authors of the study has received funding from BMY and SNY.

© 2008 CNBC.com

HOME  |  NEWS  |  MARKETS  |  EARNINGS  |  INVESTING  |  VIDEO  |  CNBC TV  |  CNBC PLUS  |  CNBC HD+
About CNBC   |   Site Map   |   Privacy Policy   |   Terms of Service   |   Advertise   |   Help   |   Feedback   |   Video Reprints
  Data is a real-time snapshot   *Data is delayed at least 15 minutes

Global Business and Financial News, Stock Quotes, and Market Data and Analysis